Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.40 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622477 | 0.88 | MEN1 (0.55) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL18269849 | 0.84 | MEN1 (0.60) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL13953201 | 0.82 | S1PR1 (0.48) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL14769843 | 0.79 | S1PR1 (0.38) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL14228475 | 0.78 | MEN1 (0.39) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL17027777 | 0.76 | MEN1 (0.49) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL17027745 | 0.76 | MEN1 (0.49) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL17027861 | 0.76 | MEN1 (0.49) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL12314891 | 0.76 | S1PR1 (0.69) | CYP3A4S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL17027781 | 0.76 | MEN1 (0.49) | MEN1USP2ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| WO-2008083280-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | MEN1 4221/4885USP2 2226/4885ALDH1A1 1469/4885 |
| US-20090042772-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | CPT1A, CPT1B, PNLIP | MEN1 2851/4885USP2 2118/4885ALDH1A1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.